TY - JOUR
T1 - Undertreatment of people with major depressive disorder in 21 countries
AU - Thornicroft, Graham
AU - Chatterji, Somnath
AU - Evans-Lacko, Sara
AU - Gruber, Michael
AU - Sampson, Nancy
AU - Aguilar-Gaxiola, Sergio
AU - Al-Hamzawi, Ali
AU - Alonso, Jordi
AU - Andrade, Laura
AU - Borges, Guilherme
AU - Bruffaerts, Ronny
AU - Bunting, Brendan
AU - De Almeida, Jose Miguel Caldas
AU - Florescu, Silvia
AU - De Girolamo, Giovanni
AU - Gureje, Oye
AU - Haro, Josep Maria
AU - He, Yanling
AU - Hinkov, Hristo
AU - Karam, Elie
AU - Kawakami, Norito
AU - Lee, Sing
AU - Navarro-Mateu, Fernando
AU - Piazza, Marina
AU - Posada-Villa, Jose
AU - De Galvis, Yolanda Torres
AU - Kessler, Ronald C.
PY - 2017/2/1
Y1 - 2017/2/1
N2 - Background Major depressive disorder (MDD) is a leading cause of disability worldwide. Aims To examine the: (a) 12-month prevalence of DSM-IV MDD; (b) proportion aware that they have a problem needing treatment and who want care; (c) proportion of the latter receiving treatment; and (d) proportion of such treatment meeting minimal standards. Method Representative community household surveys from 21 countries as part of the World Health Organization World Mental Health Surveys. Results Of 51 547 respondents, 4.6% met 12-month criteria for DSM-IV MDD and of these 56.7% reported needing treatment. Among those who recognised their need for treatment, most (71.1%) made at least one visit to a service provider. Among those who received treatment, only 41.0% received treatment that met minimal standards. This resulted in only 16.5% of all individuals with 12-month MDD receiving minimally adequate treatment. Conclusions Only a minority of participants with MDD received minimally adequate treatment: 1 in 5 people in high-income and 1 in 27 in low-/lower-middle-income countries. Scaling up care for MDD requires fundamental transformations in community education and outreach, supply of treatment and quality of services. Declaration of interest In the past 3 years, R.C.K. received support for his epidemiological studies from Sanofi Aventis, was a consultant for Johnson & Johnson Wellness and Prevention and served on an advisory board for the Johnson & Johnson Services Inc. Lake Nona Life Project. R.C.K. is a co-owner of DataStat Inc., a market research firm that carries out healthcare research.
AB - Background Major depressive disorder (MDD) is a leading cause of disability worldwide. Aims To examine the: (a) 12-month prevalence of DSM-IV MDD; (b) proportion aware that they have a problem needing treatment and who want care; (c) proportion of the latter receiving treatment; and (d) proportion of such treatment meeting minimal standards. Method Representative community household surveys from 21 countries as part of the World Health Organization World Mental Health Surveys. Results Of 51 547 respondents, 4.6% met 12-month criteria for DSM-IV MDD and of these 56.7% reported needing treatment. Among those who recognised their need for treatment, most (71.1%) made at least one visit to a service provider. Among those who received treatment, only 41.0% received treatment that met minimal standards. This resulted in only 16.5% of all individuals with 12-month MDD receiving minimally adequate treatment. Conclusions Only a minority of participants with MDD received minimally adequate treatment: 1 in 5 people in high-income and 1 in 27 in low-/lower-middle-income countries. Scaling up care for MDD requires fundamental transformations in community education and outreach, supply of treatment and quality of services. Declaration of interest In the past 3 years, R.C.K. received support for his epidemiological studies from Sanofi Aventis, was a consultant for Johnson & Johnson Wellness and Prevention and served on an advisory board for the Johnson & Johnson Services Inc. Lake Nona Life Project. R.C.K. is a co-owner of DataStat Inc., a market research firm that carries out healthcare research.
UR - http://www.scopus.com/inward/record.url?scp=85013762710&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85013762710&partnerID=8YFLogxK
U2 - 10.1192/bjp.bp.116.188078
DO - 10.1192/bjp.bp.116.188078
M3 - Review article
C2 - 27908899
AN - SCOPUS:85013762710
VL - 210
SP - 119
EP - 124
JO - British Journal of Psychiatry
JF - British Journal of Psychiatry
SN - 0007-1250
IS - 2
ER -